Senator Lloyd and B.A. Bentsen Center for Stroke Research
Jaroslaw Aronowski, PhD., Professor
"Novel Cell Therapy for Treatment of Hemorrhagic Stroke via Improving Hematoma Clearance with Cell Therapy"
- Clearance of toxic blood from brain matter after hemorrhagic stroke is essential to allow for improved neurological recovery. Dr. Aronowski’s Bentsen Stroke Center funded project focuses on pre-clinical studies, testing whether the body’s own scavenging cells (microglia/macrophages),that have been genetically or pharmacologically modified to act as more efficient scavengers, can be used to improve blood removal from brain after hemorrhagic stroke. This approach is expected to reduce brain damage inflicted by the toxic blood and improve post-stroke recovery.
Qilin Cao, MD., Associate Professor
"Human ESC and iPSC Derived Neural Precursors for Stroke Therapy"
- Stroke is a common and debilitating neurological disorder that lacks adequate therapies. Transplantation of neural stem cells (NSC) could be one of the most promised novel reparative strategies to promote functional recovery after stroke. In this funded application, we will develop strategies to turn stroke patient’s skin cells into neural stem cells in the culture dish and then test the therapeutic efficacy and long-term safety of patient-specific neural stem cells in clinical relevant stroke animal model. These studies will provide a solid foundation to develop the safe and effective stem cell-based restorative therapies for stroke in the near future.
Charles S. Cox, Jr., MD., Professor
"Amniotic Fluid Derived MSCs for Neurological Injury Associated with Repair of Congenital Heart Disease"
- Dr. Cox's Bensten Stroke Center project uses amniotic fluid derived mesenchymal stromal cells to treat the neurological injury associated with single ventricle physiology of patients with severe congenital heart disease that requires cardiopulmonary bypass in the conduct of corrective/palliative surgery. As a part of this program, a working cell bank of AFMSCs has been created in conjunction with the Texas Fetal Center and the Griffin Stem Cell Research Laboratory which is a cGMP, FDA Registered Cell Production Facility located in the BBSB on the South Campus of UTHealth.
Pramod Dash, PhD., Professor
"Multipotent Adult Progenitor Cells (MAPCs) and Inflammation"
- Research in Dr. Dash's laboratory is focused on developing treatments to improve the function of the injured brain. In order to achieve this, his lab examines the cellular and molecular mechanisms that are triggered by brain injury which contribute to cognitive impairments. Guided by these changes, we develop mechanism-based treatment strategies using pharmacological agents, molecular techniques and adult stem cells to to reduce injury-induced brain pathologies and cognitive dysfunctions. As a part of the Bentsen Stroke Research program, we will examine the molecular mechanism by which intravenously administered adult stem cells can help limit brain damage.
Ying Liu, MD., PhD.,Assistant Professor
Jiaqian Wu, PhD., Assistant Professor
"Identification of Therapeutic Targets to Increase Neuronal Differentiation Efficiency of hiPSC-derived NCSs in Treating Stroke"
- Dr. Liu and Wu's Bentsen Stroke Center funded project is focused on investigation of the gene expression and the regulatory mechanisms that distinguish human induced pluripotent stem cell (hiPSC)-derived neural stem cells (NSCs) and hiPSC-derived neuronal restricted progenitors (NRPs). The identification of these differences is essential for understanding the molecular mechanism of neuronal differentiation of hiPSC-NSCs and finding novel therapeutic targets to enhance neuron differentiation efficiency of hiPSC-NSCs in treating stroke.
Sean Savitz, MD., Associate Professor
"Biological Targets of Stem Cell Therapy for Stroke Recovery"
- Dr. Savitz's regenerative program is testing some of the first cell therapies in patients with acute stroke. In his Bentsen Project, his team is identifying potential biological targets of stem cell therapies in stroke patients. They are performing neuroimaging studies to assess how stem cells may reduce brain damage are modulate the immune system after stroke. In addition, the team is also testing new types of stem cell therapies that may have longer therapeutic time windows for subacute to chronic stroke.
About the Bentsen Stroke Center
The Senator Lloyd and B.A. Bentsen Center for Stroke Research promotes research and collaboration leading to the prevention of stroke, a medical problem affecting countless individuals and families. With three-quarters of a million new or recurrent strokes each year in the U.S., research is vital to better understand, treat and help people avoid stroke. Researchers involved in the Bentsen Center - in areas including stem cell therapy, genetic predictors of stroke, induced hypothermia/hibernation, molecular imaging of the vascular system, and others - will have tremendous impact on the medical field as the center goes forward.
About Senator Lloyd Bentsen
Serving as a four-term U.S. Senator from Texas and as Secretary of the Treasury, Lloyd Bentsen, Jr. was one of the most respected and influential politicians of the twentieth century. Senator Bentsen and his wife, B.A., visualized the creation of a significant research center to combat one of this nation's leading causes of death and disability. Their generosity, and that of many others, led to the establishment of this research program that is now a major component of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases.
"We are dedicated to establishing
a center that is focused on stroke research
and I believe with all my heart that
our children and grandchildren
will benefit from the transformational work
that will be done here."
- Mrs. B.A. Bentsen
January 22, 2009
January 22, 2009 Dedication of the Senator Lloyd and B.A. Bentsen Center for Stroke Research:
February 21, 2012 Dr. Mahendra Rao visits Center for Stem Cell and Regenerative Medicine:
April 10, 2012 Bentsen Family Visit and Luncheon at the Center for Stem Cell and Regenerative Medicine:
First study to identify common variant influencing susceptibility in U.S.: